Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 5
---
essable NLS Common Shares equal to the Exchange Ratio; •option, restricted share unit, restricted share, warrant or other right issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares, shall be assumed by the Company and converted into an option, warrant, other award, or right, as applicable, to purchase NLS Common Shares in accordance with the terms of the Merger Agreement; and •each NLS Common Share issued and outstanding, each NLS Common Share acquirable upon complete conversion of the issued and outstanding NLS Preferred Shares, each NLS Common Share acquirable upon complete conversion of the issued and outstanding Preferred Participation Certificates, and each NLS Common Share acquirable upon the exercise of outstanding warrants of the Company (including, for the avoidance of doubt, pre -fundedwarrants), shall continue to remain outstanding and, in addition, be entitled to a contingent value right (“CVR”), pursuant to the terms of the Merger Agreement and the CVR Agreement. In addition, several convertible loans issued to Kadimastem will be converted into equity securities of Kadimastem upon Closing, including (1) a loan to NLS from certain lenders, including Alpha Capital Anstalt, in the amount of $1.7million; and (2) a loan from Michel Revel in the amount of NIS 3.4million. Under the Merger Agreement, any shareholder receiving NLS Common Shares in excess of a 9.99% beneficial ownership limitation as a result of the Merger, shall be issued instead pre -fundedwarrants exercisable for a number of NLS Common Shares equal to such NLS Common Shares in excess of the beneficial ownership limitation, at an exercise price equal to the par value of the NLS Common Shares as of the Effective Time, which, in any event, shall be no less than CHF 0.0001 per share. The Merger Agreement and the consummation of the transactions contemplated thereby have been approved by the NLS Board, and Kadimastem Board and shareholders, and the NLS Board has resolved, subject to customary exceptions, to recommend that the shareholders of the Company approve the Merger Agreement and the transactions contemplated therein. The NLS Common Shares and traded warrants are currently listed on the Nasdaq Capital Market (“Nasdaq”), under the symbols “NLSP” and “NLSPW”, respectively. NLS has filed an additional listing application with Nasdaq, as required by